A 1-Year, Multicenter, Randomized, Open-Label Controlled Study to Evaluate the Efficacy and Safety of Cord Blood Cells Expanded With MPCs for Hematopoetic Recovery in Patients With Hematologic Malignancies After Myeloablative Treatment

Trial Profile

A 1-Year, Multicenter, Randomized, Open-Label Controlled Study to Evaluate the Efficacy and Safety of Cord Blood Cells Expanded With MPCs for Hematopoetic Recovery in Patients With Hematologic Malignancies After Myeloablative Treatment

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2016

At a glance

  • Drugs Rexlemestrocel-L (Primary) ; Mesenchymal stem cell therapy
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Hodgkin's disease; Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Mesoblast
  • Most Recent Events

    • 21 Jul 2016 Status changed from recruiting to active, no longer recruiting.
    • 12 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top